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Abstract
Background: Decision makers need to know whether health state values, an important component of summary
measures of health, are valid for their target population. A key outcome is the individuals’ valuation of their current
health. This experience-based perspective is increasingly used to derive health state values. This study is the first to
compare such experience-based valuations at the population level across countries.
Methods: We examined the relationship between respondents’ self-rated health as measured by the EQ-VAS, and
the different dimensions and levels of the EQ-5D-3 L. The dataset included almost 32,000 survey respondents from
15 countries. We estimated generalized linear models with logit link function, including country-specific models and
pooled-data models with country effects.
Results: The results showed significant and meaningful differences in the valuation of health states and individual
health dimensions between countries, even though similarities were present too. Between countries, coefficients
correlated positively for the values of mobility, self-care and usual activities, but not for the values of pain and anxiety,
thus underlining structural differences.
Conclusions: The findings indicate that, ideally, population-specific experience-based value sets are developed and
used for the calculation of health outcomes. Otherwise, sensitivity analyses are needed. Furthermore, transferring the
results of foreign studies into the national context should be performed with caution. We recommend future studies to
investigate the causes of differences in experience-based health state values through a single international study
possibly complemented with qualitative research on the determinants of valuation.
Background
Health state values are used to weigh the different di-
mensions of a particular health state, such as physical
functioning and mental health.1 By rendering the overall
aggregation of health they make up a key methodo-
logical step in the evaluation of health effects. The
concepts and methods used to generate health state
values have been studied and discussed continuously,
mainly considering the following questions: which health
dimensions should be valued, how to elicit these values,
and whose values should be used [1–3]? It has been
shown that such conceptual and methodological choices
affect outcomes at the population level as well as for
patient groups defined by diseases [4–7]. Consequently, it
is important for health care decision makers to be aware
of the choices underlying the value sets they base their de-
cisions on. A recent comparative study on diabetes pa-
tients, for example, concluded that “the choice of tariff
might have substantial impact on funding decisions” [8].
Health state values have been elicited using choice-
based experiments in which respondents are asked to
make trade-offs between living in a less than perfect
health state and living in full health.2 However, concerns
have been raised regarding this approach. It requires re-
spondents to assess hypothetical health states (HHS)
and, in that case, healthy respondents may focus on the
health problem they are asked to imagine, overlooking
other health domains and underestimating adaptation.
At the same, patients may have adapted to their health
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problems and be unable to predict their valuation of (or
recall how they valued) being in full health [3, 9]. It has
been argued that a different approach is needed which re-
flects the degree to which health states actually affect
people, instead of respondents’ choices or ex-ante prefer-
ences regarding different hypothetical health states [3]. In
recent years, several population-based studies used such
an experience-based approach to elicit health state values
for Germany, the U.S.A., Sweden and China [10–13]. The
experience-based approach involves a generic rating by in-
dividuals on how they feel at a particular moment, com-
plemented with concurrent descriptive information about
their health status.3 Leidl et al. were the first to estimate a
value set based on experienced health states (EHS) in
Germany, relating respondents’ EQ-VAS rating of their
own health (on a 0,100 scale) to their health status as de-
scribed by the health dimensions of the EQ-5D-3 L [10].
The results indicated that such EHS-based valuations can
differ from valuations of HHS.
To the best of our knowledge, EHS-based value sets
were derived on a national basis only. A concern at this
stage is the still limited number of countries for which
EHS-based value sets are available. As a consequence,
researchers in other countries could decide to use these
(foreign) EHS-based value sets in their national-level
analyses, similar to several studies that were based on
HHS-based value sets [14–16]. However, as valuations
may differ between countries, so may economic evalua-
tions and population health assessments based upon
them. Therefore, the transferability of these studies and
their usefulness for national-level policy making depends
on the cross-country comparability of health prefer-
ences. It can be argued that value sets should represent
national preferences since reimbursement decisions
mostly use a national perspective. More generally, health
systems may be expected to produce health outcomes in
accordance with the preferences of the population they
serve and whose means are put in use.
From a theoretical point of view, it may be expected
that health state valuations differ between countries
[17–19]. Economic and geographical circumstances and
social support systems vary between countries, affecting
the way people perceive and value health limitations. In
addition, the valuation of health states may be influ-
enced by culturally or religiously defined preferences re-
lated to health. At least, this was found in some
empirical studies on HHS-based value sets [15, 20–27].
In general, these studies concluded that cross-country
variation in health state values cannot be ignored, even
though the magnitude of the differences varied between
studies and valuation methods. For example, Badia et al.
found statistically significant differences between
Spanish and UK respondents for 35% of the health states
valued [20]. Spanish respondents placed significantly
greater value on the functional dimensions mobility and
self-care and lower value on pain and anxiety, compared
to British respondents. Similarly, Norman et al. showed
that mobility problems were considered more important
among Japanese respondents compared to respondents
from the UK, whereas opposite results were found for
pain and anxiety [25]. An important limitation of cross-
country comparisons of HHS-based value sets is the
methodological variation between studies regarding e.g.
the number and choice of health states valued by
respondents and the algorithm used to establish the
value set. For example, it was shown that methodological
variation in the transformation of negative values ex-
plained a substantial part of the difference between the
UK and US versions of HHS-based value sets for the
EQ-5D-3 L value sets [28].
In this study, we aimed to expand the evidence on dif-
ferences in health state values between countries. The
study is the first to compare EHS-based valuations
across countries. We analyse data from EQ-5D-3 L
population surveys conducted in fifteen countries be-
tween 1993 and 2002. Similar to previous national
studies [10, 29], we investigate the relationship between
respondents’ EQ-VAS rating of their own health (out-
come variable) and their descriptive health profile using
the EQ-5D-3 L. The current study provides better
generalizability of the results in comparison to previous
international comparisons of health state values, by in-
cluding 15 countries. Furthermore, using EHS-based val-
uations reduces methodological variation in terms of
transformation and estimation procedures, compared to
previous comparisons of HHS-based value sets. We
focus on two research questions: (1) Does the mean ob-
served EQ-VAS per health state (i.e., a combination of
health dimensions) differ between countries? (2) Does
the estimated value of particular health dimensions vary
across populations, both in terms of the size of their im-
pact and the ranking of dimensions? Results of the first
part are expected to show the extent to which EHS-
based valuations of particular health states vary across
countries. Results of the second part are expected to
demonstrate to what extent individual health dimensions
are valued differently.
Methods
Data
Data was provided by the EuroQol Group, covering
fifteen countries in which EQ-5D-3 L population surveys
were conducted. The EQ-5D-3 L surveys were carried
out between 1993 and 2002. All surveys used a standard-
ized version of the EQ-5D-3 L, including the EQ-VAS
and the EQ-5D-3 L descriptive profile. The translation
process of the EQ-5D-3 L surveys followed the guide-
lines proposed in the international literature [30]. Survey
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respondents were non-institutionalized persons aged
18 years and older. Sample sizes varied between 400 and
5500 observations per country; in countries with more
than one sample, samples were aggregated. In total 31,852
observations were included in the dataset. Additional
file 1 provides more details about the original studies.
EQ-VAS and EQ-5D-3 L descriptive profile
The outcome variable was the respondents’ rating of
their own health at time of the interview using the EQ-
VAS (0–100 scale ranging from the worst to the best im-
aginable health state). The main explanatory variables
were the five dimensions covered in the EQ-5D-3 L
descriptive health profile: mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression. Each re-
spondent indicated whether he/she had “no problems”,
“some problems” or “severe problems” in each of the five
dimensions thus classifying into one of 243 possible
health states. In most surveys, respondents also provided
additional information about their age, gender, and
education-level.4 Table 1 provides descriptive informa-
tion about the samples in the pooled dataset.
Analysis
We investigated the association between the EQ-VAS
and the EQ-5D-3 L descriptive health profile. Since we
focused on EHS-based valuations, there is one observa-
tion for each respondent in the dataset, in contrast to
HHS-based valuation studies in which respondents as-
sess multiple health states.
Regarding the first research question, we explored the
distribution of EQ-VAS ratings by health state as observed
in the country samples. We investigated those health
states for which reliable and detailed comparison could be
made, based on frequency of occurrence. These health
states varied in terms of severity, in one or more dimen-
sions, and covered 70% of the population analysed. We
employed nonparametric tests for ordinal data to compare
the distribution of the EQ-VAS ratings for these health
states across countries [31]. We used the Kruskal-Wallis
test, which tests whether multiple samples are from the
same population. In addition, we used the Mann-
Whitney-U test (or Wilcoxon-rank-sum test) which tests
whether two independent samples are from populations
with the same distribution. The latter was used to test the
distribution of EQ-VAS ratings country-by-country.
Regarding the second research question, we estimated
the value of particular health dimensions using regres-
sion models in which EQ-VAS ratings were regressed on
health dimensions and levels of the EQ-5D-3 L descrip-
tive profile. As shown by Leidl et al., commonly used
(generalized/ordinary) least squares regression models
for these type of data, as in e.g. [32], do not account for
two methodological issues: predictions falling outside
the original EQ-VAS range and inconsistent coefficients
(i.e. coefficients predicting a higher value for a health
state with more problems compared to a health state
with less problems). Leidl et al. found more consistent
outcomes with similar or better predictive accuracy
using: 1) a generalized linear model with a logit link
function (assuming a binomial distribution for the
dependent variable5); 2) a restriction for the coefficients
to create all non-positive parameter estimates; and 3) an
alternative specification of the explanatory variables.
Based on the consistency assumption that increases in
problems may not increase the valuation of a health
state, we employed constraints to the possible parameter
estimates in the regression model. In consequence, opti-
mal regression results were simultaneously obtained for
all parameters (which is not guaranteed when excluding
single parameters from the model).
Two variables were created for each of the five EQ-5D-
3 L dimensions: one dummy variable for having any (some
or extreme) problems versus no problems (Mobility, Self-
care, Activity, Pain and Anxiety) and one dummy variable
for having extreme problems versus no extreme (none or
some) problems (Mobility3, Selfcare3, Activity3, Pain3 and
Anxiety3).6 In this way, consistency is obtained, if param-
eter estimates are constrained as non-positive. In order to
take into account the substantial number of respondents
who did not report any problems, two intercept terms
were included: one for the group of respondents who do
not incur problems in any dimension, and one for all
others (INT1 and INT2). The basic VAS-level for people
who experienced at least one problem in one of the five
dimensions may thus differ from that for people who did
not experience any problem. Summarizing, twelve ex-
planatory variables were included reflecting the different
elements of the EQ-5D-3 L descriptive profile.
We applied this specification to our data and estimated
15 country-specific regression models to investigate the
value of different health dimensions at the country level.
Furthermore, we used the pooled dataset of all countries
to test whether the value of specific health dimensions dif-
fered significantly from one country to another. For this
pooled-data set, we estimated 12 regression models refer-
ring each to one type of explanatory variable: existence of
problems in each of the five dimensions, existence of ex-
treme problems respectively, and the two intercepts. In
each model, we included all explanatory variables while
allowing the referred variable to vary by country using
interaction terms. For example, we estimated one model
in which we tested whether the impact of some or ex-
treme mobility problems varied across countries. This
model included all twelve explanatory variables plus inter-
action terms between country dummies and the health di-
mension mobility (having some or extreme problems
versus no problems). In all pooled data models, random
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intercepts (INT1 and INT2) were used. Using likelihood
ratio tests, we then examined whether these models with
interaction terms were statistically significantly different
from models without interaction terms.
Finally, as a sensitivity analysis, we tested whether cer-
tain survey and respondent characteristics could further
explain the variation in EQ-VAS ratings, beyond the dif-
ferent health dimensions and country effects. Previous
studies showed that the data collection mode and
respondent characteristics as age and gender explained
part of the variation in health state values. Therefore, we
added a dummy variable reflecting the data collection
mode (postal survey or face-to-face interview), and
respondent characteristics age and gender to the regres-
sion model. The computations for all regression models
were performed using the NLMIXED procedure in SAS.
Results
Mean observed EQ-VAS per country for different health
states
Figure 1 shows that the mean EQ-VAS per health state
varied between countries. For example, it ranged between
81.3 (Japan) and 91.7 (Sweden) for health state 11,111 (no
problems in all dimensions); between 62.7 (Hungary) and
81.0 (Germany) for health state 11,122 (some problems in
the dimensions pain and anxiety); and between 46.8
(Greece) and 67.5 (US) for health state 21,222 (some prob-
lems in all dimensions except self-care). For the first five
health states in Fig. 1, the mean EQ-VAS differed on aver-
age 6.5 points (SD = 4.5) between countries. Differences
between countries seemed greater for health states with
more problems, but as the number of observations de-
crease with worse health, uncertainty is also increasing.
The Kruskal-Wallis tests rejected the hypothesis that all
samples were from the same population for all health
states in Fig. 1 except for the worst health state (22232).
Country-by-country comparisons using the Mann-
Whitney-U test (statistics not shown here) demonstrated
a similar pattern. These were less often significant for
health states with more problems in the EQ-5D-3 L di-
mensions, even though the mean differences between
countries were often greater. Countries at the low-end
and high-end of the EQ-VAS scale differed from all other
countries, in particular for health states including fewer
Fig. 1 Mean EQ-VAS by health state and country.
Seven frequently occurring health states were selected (see text). ARM = Armenia, BEL = Belgium, CAN = Canada, FIN = Finland, GER = Germany,
GRE = Greece, HUN = Hungary, JAP = Japan, NET = Netherlands, NZL = New Zealand, SLV = Slovenia, SPA = Spain, SWE = Sweden, UK = United
Kingdom, US = United States
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problems. For example, Japan (lowest) and Sweden (highest)
were significantly different from all other countries with re-
gard to the value of health state 11,111. At the same time,
Belgium, with a medium EQ-VAS rating for health state
11,111, differed from seven of the other countries in the
dataset. For Japan, the distribution of EQ-VAS ratings also
differed from six of the other countries for health state
11,122 but did not differ significantly from any of the
countries for health state 22,222. For the more healthy
states, the mean EQ-VAS was lowest in Hungary, Greece,
Japan and Spain, and highest in the US, Germany, Slovenia,
Sweden and the UK.
Estimated valuation of individual health dimensions
Table 2 shows the results of the country-specific regres-
sion models. As the parameter estimates were forced to
be non-positive, coefficients with a zero value indicate
that the best estimate is found on this boundary. For
most countries, having some or extreme problems with
mobility, self-care, usual activities, pain, and anxiety had
a statistically significant impact on the EQ-VAS rating
(columns Mobility-Anxiety). For the additional effect of
extreme problems, estimates were more often at the
boundary (zero) and less often statistically significant (var-
iables Mobility3-Anxiety3). In particular, the additional
effect of extreme problems in mobility or self-care was
not significant in most cases, whereas the additional
impact of extreme problems regarding pain or anxiety/de-
pression was almost always significant. Having some or
extreme problems in the pain/discomfort dimension (for
Sweden, Armenia and Hungary) or the usual activities di-
mension (for all other countries) showed a greater impact
compared to the dimensions mobility, self-care and anx-
iety. The latter two showed the smallest effect on EQ-VAS
ratings. There was much greater variation in the ranking
of dimensions when respondents had extreme problems.
Table 2 also underlines that the size of the value loss asso-
ciated with each dimension differed between countries.
The model parameters shown in Table 2 can be trans-
formed into an EQ-VAS rating.7 For example, the mean
EQ-VAS rating for health state 11,111 (no problems in all
dimensions) was similar for Armenian and Greek respon-
dents, i.e. 0.86. However, the EQ-VAS rating associated
with health state 21,111 (using the sum of the coefficients
INT2 and Mobility) differed substantially: 0.76 for Arme-
nian respondents and 0.62 for Greek respondents. In
other words, the impact of mobility problems was much
greater in Greece compared to Armenia. As another ex-
ample, the Finnish EQ-VAS rating associated with health
state 11,211 (some or extreme problems performing usual
Table 2 Coefficients country-specific regression models (yellow cells: p < 0.05)a
aARM Armenia, BEL Belgium, CAN Canada, FIN Finland, GER Germany, GRE Greece, HUN Hungary, JAP Japan, NET Netherlands, NZL New Zealand, SLV Slovenia, SPA
Spain, SWE Sweden, UK United Kingdom, US United States
INT1 = Intercept - no problem in all dimensions; INT2 = Intercept – at least some problem in one dimension; Mobility = Some or extreme problems in Mobility;
Selfcare = Some or extreme problems in Selfcare; Activity = Some or extreme problems in Activity; Pain = Some or extreme problems in Pain; Anxiety = Some or
extreme problems in Anxiety; Mobility3 = Extreme problems in Mobility; Selfcare3 = Extreme problems in Selfcare; Activity3 = Extreme problems in Activity;
Pain3 = Extreme problems in Pain; Anxiety3 = Extreme problems in Anxiety
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activities and no problems in all other dimensions) equals
0.74 using the sum of the Finnish coefficients INT2 and
Activity. If the value of usual activity problems would have
been similar to the UK (−.424 instead of −.590), then
health state 11,211 would be associated with an EQ-VAS
rating of 0.77.
To compare the values estimated for all possible com-
binations of health states, the countries with the highest
(Sweden) and lowest (Armenia) observed mean EQ-VAS
(Table 1) are taken as an example. Not for a single state,
values were estimated the same for both countries: for
166 states, values in Sweden were higher while for 77
states, values were higher in Armenia (Fig. 2). The slope
of the point cloud indicates equality of the overall struc-
ture of health state valuation while higher Swedish
values relate to a significant, positive intercept of 5.4
points (regression results not shown).
Table 3 shows the results of the pooled data models.
Each column represents a separate regression model in
which one of the explanatory variables (the column
header) was allowed to vary by country using interaction
terms. Only the coefficients of these country-specific
interaction terms are shown here, because they are the
main parameters of interest. Overall, the models that in-
cluded interaction terms at the level some or extreme
problems (columns Mobility-Anxiety) were significantly
different from models without these country-effects. The
country-specific interaction terms showed significant dif-
ferences (p < 0.01) at the level some or extreme prob-
lems for all countries, except for Japan in the
dimensions mobility and self-care. For example, having
some or extreme mobility problems was associated with
greater value loss in Germany and Greece compared to
all other countries. The impact of pain was largest in
Armenia and Slovenia. The models with interaction
terms for extreme problems (columns Mobility3-
Anxiety3) were significantly different from models
without interaction terms. At the same time, the
country-specific interaction terms were less often statis-
tically significant. We found no country-specific effect
for severe mobility problems and self-care problems in
Hungary, Spain, Canada and the Netherlands. The table
also shows a particular association between the intercept
term and interaction terms for some countries. For
Fig. 2 Estimated values for all 243 health states of the EQ-5D-3 L for Sweden and Armenia
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example, for Japan both the intercept term and the coef-
ficients for mobility, self-care and activity were relatively
low. In other words, Japanese respondents reported a
relatively low EQ-VAS for health state 11,111 (no prob-
lems in all dimensions) in combination with the smallest
value losses for problems with mobility, self-care and
usual activities. In contrast, German respondents dem-
onstrated the strongest effects in these three dimensions.
Furthermore, Japan and four more countries (ARM,
NET, SPA and SWE) showed a similar pattern in weak
effects compared to GER, CAN, GRE and SLV with an
opposite pattern of rather strong value decreases having
such problems.
Table 4 shows the ranking of countries for each model
based on these coefficients. A high rank is equal to a
relatively low value for a country in a particular dimen-
sion. A strongly positive correlation appeared between
the interaction terms for mobility, self-care and usual ac-
tivities (Spearman rank correlation between 0.8 and 0.9).
Populations from countries with a relatively high value
for mobility problems thus generally also attributed a
high value to problems with self-care and usual activ-
ities. At the same time, there was little correlation be-
tween the interaction terms for pain and anxiety and
those for the other dimensions.
Figure 3 visualizes the range of the interaction term
coefficients between countries for each model. It indi-
cates that differences between countries were lower for
health states with some or extreme problems than for
those with extreme problems and for the intercept
terms, the latter indicating the value of no problems.
Finally, in the sensitivity analysis, the data collection
mode and the respondent characteristics age and gender
were found to have a statistically significant impact in all
models (results not shown here). On average, the inclu-
sion of these variables reduced the country-specific
interaction term coefficients, even though in some cases
opposite results were found. Differences between
countries changed to some extent, though the correl-
ation between the interaction term coefficients before
and after this adjustment was greater than 0.9 for 8 out
of 12 models.
Discussion
In this study, we investigated EHS-based valuations from
a population perspective, using pooled data from 15
countries and standardized, novel methods. The study is
the first to compare valuations based on experienced
health states across countries. Previous international
studies focused on cross-country differences in HHS-
Table 3 Interaction term coefficients for pooled-data regression models (yellow cells: p < 0.05)a
aARM Armenia, BEL Belgium, CAN Canada, FIN Finland, GER Germany, GRE Greece, HUN Hungary, JAP Japan, NET Netherlands, NZL New Zealand, SLV Slovenia, SPA
Spain, SWE Sweden, UK United Kingdom, US United States
INT1 = Intercept - no problem in all dimensions; INT2 = Intercept – at least some problem in one dimension; Mobility = Some or extreme problems in Mobility;
Selfcare = Some or extreme problems in Selfcare; Activity = Some or extreme problems in Activity; Pain = Some or extreme problems in Pain; Anxiety = Some or
extreme problems in Anxiety; Mobility3 = Extreme problems in Mobility; Selfcare3 = Extreme problems in Selfcare; Activity3 = Extreme problems in Activity;
Pain3 = Extreme problems in Pain; Anxiety3 = Extreme problems in Anxiety
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Fig. 3 Range of the county-specific interaction term coefficients by EQ-5D-3 L health dimensions – maximum (green), median (red) and minimum (blue).
As the parameter estimates were forced to be non-positive, coefficients with a zero value indicate that the best estimate is found on this boundary.
Coefficients with zero value were found in almost all dimensions. INT1 = Intercept - no problem in all dimensions; INT2 = Intercept – at least some problem
in one dimension; Mobility = Some or extreme problems in Mobility; Selfcare = Some or extreme problems in Selfcare; Activity = Some or extreme
problems in Activity; Pain = Some or extreme problems in Pain; Anxiety = Some or extreme problems in Anxiety; Mobility3 = Extreme problems in
Mobility; Selfcare3 = Extreme problems in Selfcare; Activity3 = Extreme problems in Activity; Pain3 = Extreme problems in Pain; Anxiety3 = Extreme
problems in Anxiety
Table 4 Ranking of countries (1-country with lowest value; 11-country with highest value) according to the interaction term
coefficientsa
INT1 INT2 Mobility Selfcare Activity Pain Anxiety Mobility3 Selfcare3 Activity3 Pain3 Anxiety3
ARM 10 11 5 7 2 15 1 12 9 5 4 2
BEL 8 7 2 6 10 6 13 11 1 14 11 8
CAN 12 6 10 13 12 8 6 1 1 7 3 13
FIN 6 8 6 11 13 10 12 10 14 10 7 6
GER 4 4 14 14 15 9 9 1 1 13 2 11
GRE 11 15 15 3 14 2 2 15 1 1 14 4
HUN 14 12 12 8 3 12 8 1 13 2 1 3
JAP 15 13 1 1 1 5 10 1 1 9 10 12
NET 9 10 4 5 5 4 4 1 10 12 12 7
NZL 7 9 8 15 4 1 5 1 1 15 9 15
SLV 5 3 13 12 9 13 11 1 15 4 13 1
SPA 13 14 3 4 6 3 3 1 12 6 6 5
SWE 1 2 9 1 8 14 15 1 1 11 15 14
UK 3 5 7 10 7 7 14 14 11 8 5 10
US 2 1 11 9 11 11 7 13 1 3 8 9
aARM Armenia, BEL Belgium, CAN Canada, FIN Finland, GER Germany, GRE Greece, HUN Hungary, JAP Japan, NET Netherlands, NZL New Zealand, SLV Slovenia, SPA
Spain, SWE Sweden, UK United Kingdom, US United States
INT1 = Intercept - no problem in all dimensions; INT2 = Intercept – at least some problem in one dimension; Mobility = Some or extreme problems in Mobility;
Selfcare = Some or extreme problems in Selfcare; Activity = Some or extreme problems in Activity; Pain = Some or extreme problems in Pain; Anxiety = Some or
extreme problems in Anxiety; Mobility3 = Extreme problems in Mobility; Selfcare3 = Extreme problems in Selfcare; Activity3 = Extreme problems in Activity;
Pain3 = Extreme problems in Pain; Anxiety3 = Extreme problems in Anxiety
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based value sets (see e.g. [7, 21]). We first studied the
mean EQ-VAS ratings associated with particular health
states and found that these varied between countries.
Differences were most evident for health states with
fewer problems and for countries at the low-end and
high-end on the EQ-VAS scale. Next, we studied the im-
pact of the individual health dimensions and found that
different populations appear to rank the dimensions and
problem levels of the EQ-5D-3 L in different ways. For
example, the impact of having some or extreme prob-
lems in the pain dimension was relatively high (com-
pared to other dimensions) for Armenian and Swedish
respondents, while it was low for respondents from New
Zealand. In most countries, having some or extreme
problems in the usual activities dimension had the lar-
gest impact, which shows that similarities between coun-
tries were present too. The magnitude of the health
dimensions’ coefficients also varied between countries,
which will translate into non-negligible differences in
terms of health outcomes. As illustrated in the results
section, the variation in coefficients may very well gener-
ate a 7-point difference on the EQ-VAS 0–100 scale,
which was considered a minimally important difference
from a clinical perspective in one study [33]. Estimations
for all possible combinations of health dimensions also
illustrated that systematic differences in terms of valu-
ation may exist (Fig. 2). At the same time, even though
individual health dimensions may be valued differently
across countries, we did find a positive correlation be-
tween the valuation of mobility, self-care and usual ac-
tivities. No correlation was found between the valuation
of pain or anxiety and all other dimensions (a previous
study found a similar pattern for Spanish respondents,
see [20]). This indicates that the pain/discomfort and
anxiety/depression dimensions represent different types
of health problems compared to mobility, self-care and
usual activities, which are valued differently as a result.
At the level of extreme problems, differences between
countries were less clear and more often not significant.
In spite of our standardized approach, we cannot ex-
clude that methodological differences caused some of
the variation between countries. The underlying
population-surveys varied regarding the year in which
the survey was conducted, the interview mode (postal or
face-to-face interview), and the sampling procedure. In
the regression models, interview mode was found to
affect EQ-VAS ratings yet it did not change cross-
country differences substantially, in particular regarding
the relative importance of the different dimensions (see
Additional file 2). Differences in study year may have af-
fected the results, in case the VAS valuation of health
changes over time due to e.g. changes in the health or
social care system that affect valuation. To our best
knowledge, there is no evidence on this issue regarding
the samples used in this study, however. Differences in
sampling procedures are described in Additional file 1.
Not all studies reached the aim of including a represen-
tative sample of the underlying population, but differ-
ences in the distribution by age and gender across
studies were taken into account in the regression model.
After adjusting for differences in the distribution of
these respondent characteristics and the interview mode,
cross-country differences remained similar. Therefore,
we argue that differences in health values between countries
cannot be ignored. Interestingly, these differences may not
necessarily reflect differences in the economic position of
countries. Both wealthier and less-wealthier countries were
found to value, for example, the reduction by some or
extreme problems in mobility much heavier than other
countries in the sample.
The existence of cross-country differences in EHS-
based valuations resembles the results from previous
studies on HHS-based value sets, yet our findings also
differ in some respects. Remarkably, some or extreme
problems with usual activities was associated with a
large reduction of the EQ-VAS in all countries, whereas
this dimension was much less important in most HHS-
based value sets [24]. This may confirm the finding from
Leidl et al.’s national studies that the two approaches
may generate value sets with different characteristics at
the population level. As argued in the introduction,
EHS-based value sets can be used as an alternative for
the traditional HHS-based value set. The EHS-based
value set developed for Germany has, for example, been
used to test the validity of the EQ-5D-3 L in specific pa-
tient groups [6, 34–37]. Recently, EHS-based value sets
have also been used in clinical studies in Sweden, in line
with the recommendation of the Swedish guidelines on
economic evaluation to use the patient’s perspective [8,
38, 39]. In case the approach will be applied in an inter-
national setting, it becomes important to take cross-
country differences in health values into account. For
example, multinational clinical trials planning to use
EHS-based values may not rely on a single value set
from one country but should regard the need to adapt
values to decision-specific contexts by using a respective
value set, and to control for eventual sensitivity of re-
sults when basing evaluation on this country-specific
valuation. In addition, our study confirms that re-
searchers should be cautious when transferring health
outcomes, based on EHS-based value sets, from foreign
studies into national calculations. This may lead to in-
valid conclusions for their target population. Results also
confirm that a simple adjustment formula does not seem
to exist, because respondents in one country did not
attach greater or smaller value to all dimensions. Rather,
this pattern fluctuated between the different health di-
mensions and levels. Eventually, the findings warn
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decision makers both against using original EQ-VAS
valuations alone without considering eventual adapta-
tion to country context, as well as against the unre-
flected transfer of results derived from value sets of
other countries.
The results must be interpreted with the following
limitations in mind. The main methodological issues
related to the EQ-VAS instrument are context bias, end-
of-scale bias and response spreading [2, 40]. The use of
the EQ-VAS to establish health state values has been cri-
ticised because of a perceived lack of theoretical founda-
tion, yet Parkin and Devlin showed that it does have a
theoretical foundation in (psychometric) measurement
theory [40]. Context bias means that the value of a par-
ticular health state depends on which health state it is
compared with. This relates to experiments in which
respondents value multiple health states (HHS-based
value set), yet in this study we used the single EQ-VAS
rating associated with the current health state of the
respondents. Dolan and Kahneman argued that the use-
fulness of EQ-VAS-type ratings also depends on any
other comparisons respondents make at time of the as-
sessment, e.g. between themselves and other people [9].
Based on our data we however could not assess whether
this led to systematic cross-country variation and should
be considered a measurement distortion. By focusing on
respondents’ valuation of their current health state, this
study could not consider the anchor point death as in
HHS-based valuation studies. In HHS-based approaches,
the value of death is commonly defined as zero and used
as anchor point to adjust for differential response behav-
iour. There is also methodological discussion on how to
further develop such anchoring in HHS-based valuation
[41]. Previous population level studies with and without
anchoring yet indicated that the difference may be lim-
ited [42]. For the examples of patients with heart disease
and with inflammatory bowel disease, it has further been
found that non-anchored VAS-based value sets correlate
better or the same with accepted clinical measures as
anchored, utility-based value sets [35, 37]. When calcu-
lating quality-adjusted survival in the experience-based
approach, death is also zero because of zero survival
time. Not attributing a value to death in the experience-
based approach implies that negative valuations for
health states do not exist, in contrast to traditional
QALY calculations. Another point, end-of-scale bias
refers to respondents avoiding the end-points of the
EQ-VAS-scale. The latter may have affected our cross-
country comparisons (the regression coefficients) if re-
spondents in country A were more inclined to avoid
end-points compared to respondents in country B. Al-
though a substantial proportion of the respondents did
report a EQ-VAS rating of (around) 100, the issue could
not be tested with the data at hand.
In addition to these EQ-VAS-related issues, we should
note that we did not include interaction terms between
the different EQ-5D-3 L dimensions and levels. This
would allow the effect of e.g. mobility to vary by differ-
ent levels of self-care. However, previous studies on
health valuation showed mixed results regarding model
fit improvement after the inclusion of such interaction
terms [24]. Moreover, adding multiplicative terms in-
creases data requirements and makes interpretation of
the model results much more complex. Another limita-
tion was the limited sample size of some of the surveys.
More importantly, the number of respondents with ex-
treme problems in any or several dimensions was limited
(the surveys did not include institutionalized persons
and certain health problems may have hindered more se-
verely ill people from participation). Therefore, there
were relatively little EHS-based values for these dimen-
sions, which reduced the precision of the estimates. In
addition, it was unclear whether all types of respondents,
according to the characteristics that may affect health
valuation, were represented in the surveys. There is little
evidence on the impact of respondent characteristics on
health valuation though and we tested the impact of dif-
ferences in distributions by age and sex. Finally, we ap-
plied a standardized methodology to an international
data set provided by the EuroQol Group. For Sweden
and Germany EHS-based value sets have been developed
elsewhere using significantly larger and more recent
samples [10, 11]. This should be considered before using
respective data from this study. We cannot exclude that
for some of the countries analyzed specification tests
would suggest a different model-specification to be bet-
ter. However, the main goal of this study was to compare
the valuation of dimensions across countries. For rea-
sons of comparability, we preferred using an identical re-
gression framework for all samples.
Conclusion
In sum, we explored international differences in EHS-
based valuations. Decision makers, who want to focus
on patient or individuals’ valuations when considering
the effectiveness of medical interventions, may find
EHS-based valuations a useful alternative to HHS-
based valuations. When determining the effectiveness
of a medical intervention, patients and physicians
typically consider what has actually happened rather
than preferences regarding what could occur. As one
important consequence, the use of such EHS-based
valuations has the potential to better integrate the
assessment of medical effectiveness and cost-
effectiveness. Overall, the results indicate that EHS-
based valuations differ between countries, at least for
the countries included in this study and for the di-
mensions and levels covered by the EQ-5D-3 L. This
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may depend upon different valuations of health prob-
lems, though systematic patterns explaining these
differences between countries, or identification of
clusters of countries similar in valuation remain to be
recognized. Since health state values are an important
input parameter in population health comparisons
and evaluations of health interventions, these findings
should be taken into account when nationally inter-
preting valuations from other countries, but also in
international comparative studies. We recommend
future research to focus on the causes of differences
in health valuation through a single international
study (at one point in time) possibly complemented with
qualitative research on the determinants of health values.
Endnotes
1For example, the EQ-5D-3 L descriptive profile in-
cludes the following dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
Each dimension has three levels: severe problems, some
problems, and no problems.
2Most often, the Time Trade Off or the Standard
Gamble technique is used. See e.g. Brazier et al. [9].
3Dolan and Kahneman preferred ‘moment-to-moment
measurements’ such as the day reconstruction method
in which people are asked to rate on a single scale how
they felt the day before [11]. However, the latter instru-
ments have been applied to a limited extent and require
further development, particularly in the area of health.
4The education variable comprised three levels (low,
medium, and high) based on two questions: “left school at
minimum age?” & “having a degree or professional qualifi-
cation?”. Yes&No = low education, No&No = medium
eductation, No/Yes&Yes = high education. In a few
countries, additional questions were used to identify the
level of education.
5As explained in Leidl et al.: “The binomial distribu-
tion can be seen to reflect a (large) series of experiments
in which a person with the true health state of p is being
confronted with a number randomly drawn from the
(0,1) range. This number is said to reflect a well-defined
health state. The respondent is then asked whether or not
his/her health state is at least as good as this health
state. The share of experiments in which this person is
expected to agree is p” [33]
6Previous HHS-based valuation studies used the fol-
lowing two variables for each dimension: a three-level
ordinal variable (no, some, severe problems) and a
dummy variable for severe problems versus no or some
problems.
7Transformation is based on the formula exp sumð Þ1þ exp sumð Þ ,
where sum equals the sum of the coefficients related to
a particular health state.
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